BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Stem Cells » Page 5

ShiftBio Partners with RoosterBio to Accelerate Development of a Novel Genetically Engineered Exosome, SBI-102 for Rare Diseases and Cancer

April 26, 2022 By Cade Hildreth (CEO) Leave a Comment

RoosterBio and ShiftBio
RoosterBio’s MSC-derived exosome bioprocess technology platform enables accelerated development of ShiftBio’s lead therapeutic candidate via a scalable cGMP manufacturing process in bioreactors, downstream purification, and analytical characterization.

Seoul, South Korea and Frederick, MD, April 26, 2022 – ShiftBio, a leader in the development of innovative exosome platform technologies, announced today a strategic partnership with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services. This partnership will accelerate ShiftBio’s therapeutic candidates, starting with SBI-102 (Stem cell-derived exosomes expressing a therapeutic ligand), into the clinic. [Read more…]

Filed Under: Exosomes, Press Releases, Stem Cell News, Stem Cells

TreeFrog Therapeutics Launches a $100,000 Research Grant in Regenerative Medicine

April 19, 2022 By Cade Hildreth (CEO) Leave a Comment

TreeFrog Therapeutics Spaceshot Grant

Bordeaux, France / April 19th, 2022 – TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced the launch of The Stem Cell SpaceShot Grant, a $100,000 research funding in the field of stem cell biology and regenerative medicine. [Read more…]

Filed Under: iPS Cells, Press Releases, Stem Cell News

Who Is CryoHoldco? Latin America’s Largest Cord Blood Bank

April 16, 2022 By Cade Hildreth (CEO) Leave a Comment

CryoHoldco is a stem cell bank holding company that is the market leader in Latin America and one of the top 10 largest cord blood banks in the world. CryoHoldco is now seven times larger than any other stem cell bank in Latin America with over 275,000 stem cell units in storage.

[Read more…]

Filed Under: Cord Blood, HSCs, MSCs, Stem Cells Tagged With: cord blood, CryoHoldco, news

Overcoming major challenges in cardiac drug discovery using human induced pluripotent stem cell technology

April 16, 2022 By Cade Hildreth (CEO) Leave a Comment

Cardiac Drug Discovery hiPSC Technology

Highlights

  • The biggest opportunity for success in cardiac drug discovery and development is to make these processes more efficient and affordable, since they carry relatively higher risk of clinical trial failure compared to other disciplines.
  • Human iPSC technology is increasingly utilized to develop disease models that reliably mimic the diversity of patient pathogenicity and disease severity in vitro.
  • Phenotypic screening based on iPSC-derived disease models is making cardiac drug discovery more time and cost effective by enabling target-agnostic studies and increasing the translational power of early drug discovery outcomes.

[Read more…]

Filed Under: iPS Cells, Stem Cells

Treefrog Therapeutics Expands Board with New Independent Members from the Cell Therapy Industy

April 14, 2022 By Cade Hildreth (CEO) Leave a Comment

Treefrog Therapeutics Expands Board
• Elsy Boglioli, former Chief Operating Officer at French cell therapy biotech Cellectis, founder and Chief Executive Officer of biotechnology consulting practice Bio-Up, joins as Chair of the Board
• Melissa Carpenter, PhD, Chief Scientific Officer of US-based cell & gene therapy biotech ElevateBio’s Regenerative Medicine unit, joins as independent board member.

[Read more…]

Filed Under: Cell Therapy, iPS Cells, Press Releases, Stem Cell News, Stem Cells

  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 178
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97

Featured Posts

Cord Blood Market Segmentation

Cord Blood Market Segmentation – Biobanking, HSCT, Cellular Therapy, Genetic Manipulation, & Research Tools

CAR-T Companies

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.